 |
SKDK and ICR handle Intra-Cellular Therapies as it is getting acquired by Johnson & Johnson for $14.6B.
J&J is offering $132 for each of the Intra-Cellular shares that trade on the NASDAQ.
The Financial Times reports the transaction is the biggest biotech deal since Pfizer acquired Seagen in 2023 for $46B.
Intra-Cellular works on treatments for central nervous system disorders—including major depressive disorder, generalized anxiety disorder and Parkinson’s disease.
Its Caplyta, a once-daily pill, is the only treatment that the Food & Drug Administration has approved to treat adults with schizophrenia and episodes associated with bipolar disorder depression.
About 2.4M adults live with schizophrenia, while 6.1M suffer from bipolar disorder.
Intra-Cellular CEO Sharon Mates said J&J ownership will enable her Bedminster, NJ-based company to reach even more patients around the world.
SKDK’s Erin Weinstein handles media for Intra-Cellular, while Juan Sanchez works Wall Street.
Jenn Kettnich, who has more than 15 years of financial communications experience, has joined Liftoff Mobile as VP-investor relations following completion of its recent IPO.
Joele Frank handles Crinetics Pharmaceuticals as the specialist for treatments for endocrine diseases agrees to get acquired by Vertex Pharmaceuticals in a deal pegged at $8.8B.
Teneo represents Honeywell spin-off Solstice Advanced Materials as it buys Collected Strategies client Element Solutions in a deal pegged at $14.5B.
Dallas-based Throughline Global Advisors advised Principal Mineral as it acquired Isola Group, maker of copper-clad laminates used in printed circuit boards.
oele Frank works for satellite operator Iridium Communications as it gets acquired by space company Rocket Lab in a deal worth $8B.
